Donate

In the News

Discover the latest news from the Pulmonary Hypertension, including advocacy updates, research articles and event coverage.

Recent news

Dislaying 313 — 318 of 360
  • Support Group Forms Book Club AliciaKubes-400×320
    Support Group Forms Book Club

    The New York City-Manhattan Support Group recently launched a book club to provide new opportunities for people with pulmonary hypertension (PH) to engage online. Leader Alicia Kubes started the support group in 2018 and has been expanding its focus since the pandemic began. The online group aims to discuss books through the lens of living with PH; patients throughout the U.S. are welcome to attend the June 9 meeting.

  • PHA Updates its COVID-19 Policy
    PHA Updates its COVID-19 Policy

    The Pulmonary Hypertension Association (PHA) recently updated its COVID-19 policy to reflect the Centers for Disease Control and Prevention guidelines. The policy focuses on individual responsibility at PHA events to use proven methods to reduce and prevent transmission.

  • Detroit Walk Raises Almost $7K for PHA
    Detroit Walk Raises Almost $7K for PHA

    The Detroit pulmonary hypertension (PH) community raised $6,795 for the Pulmonary Hypertension Association O2breathe walk on May 6. The event featured Tammera Tubolino, who recounted her sister Kristy’s CTEPH journey. The event also featured longtime support group leader Carla Kinsey.

  • CEO Update: Join Us for World PH Day 2023 CEO Update Matt
    CEO Update: Join Us for World PH Day 2023

    Please join the Pulmonary Hypertension Association and more than 80 other patient organizations next week in observing World PH Day. Since 2012, the global pulmonary hypertension (PH) community has come together May 5 to bring attention to this rare lung disease. Whether you have PH, care for someone with PH or are a health care professional, please help us mark this important day.

  • Update Your Calendar With New PHA 2024 Dates Matt_attendees_PHA2022_800x311
    Update Your Calendar With New PHA 2024 Dates

    You might have noticed that we’ve moved the date for PHA 2024 International PH Conference and Scientific Sessions. The conference is now set for Aug. 15-18, 2024, at the JW Marriott in Indianapolis. The new date allows the Scientific Sessions to focus on new guidance and findings from the seventh World Symposium on Pulmonary Hypertension (PH).

  • What to Do When You’re Running Out of Medication
    What to Do When You’re Running Out of Medication

    Like many in the pulmonary hypertension community, you know the stress of waiting for prescription refills and worrying whether they will arrive in time. Although specialty pharmacies try to avoid medication disruptions, errors sometimes happen. The Pulmonary Hypertension Association (PHA) asked several specialty pharmacies about what to do when you’re at risk of missing a dose or need an early refill. Visit the new resource page in PHA’s Insurance Guide.

PH in the News

Ralinepag shows delayed disease progression in PAH study

Ralinepag met a primary goal to delay disease progression in a Phase 3 study, United Therapeutics announced. The study met several secondary goals, including six-minute walk distance.

Read more

Pulmovant completes Phase 2 study enrollment for PH-ILD drug

Pulmovant has completed enrollment for its Phase 2 PHocus clinical trial to evaluate a once-daily inhaled treatment for PH-ILD. Mosliciguat helps widen blood vessels and could have anti-inflammatory and anti-fibrotic properties.

Read more

Gossamer announces topline results from Phase 3 seralutinib study

Gossamer Bio’s Phase 3 seralutinib trial narrowly missed its primary endpoint goal to show improved six-minute walk distance at week 24, according to its news release. An unexpectedly large improvement in walk distance in the placebo group appeared in part to influence the outcome, Gossamer says. The company noted encouraging findings in key secondary goals, including reductions in NT-proBNP, improvements in clinical status and lower risk scores. The study also showed meaningful treatment effects in patients with intermediate and high-risk PH, Gossamer explains in a document for patients (pdf).

Read more
Industry news

Back to Top